Short interest for Biomea Fusion gives investors a sense of the degree to which investors are betting on the decline of Biomea Fusion's stock. Short interest data is updated every two weeks.

Biomea Fusion Stock (NASDAQ:BMEA), Short Interest Report

Biomea Fusion

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFIB

AKTS

ALPN

ALTI

AMSC

BMEA

CCTG

CISS

CMND

CNXC

COLB

CRGE

EPIX

IMMX

INSG

LVTX

MRAI

ONCO

PCSA

PHUN

PROP

RDHL

RVSN

TSLA

VERA

VIRT

VSME

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday.

Shares of  Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.

Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday

Long Ideas

Media

COST

EPRT

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended moving on from  Tidewater Inc.  (NYSE: TDW). &#34;It’s moved too much,&#34; he added.

Jim Cramer Says Move On From This Energy Stock: &#39;It&#39;s Moved Too Much&#39;

Biomea Fusion Inc

Throughout the last three months, 20 analysts have evaluated Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.15, a high estimate of $32.00, and a low estimate of $15.00. Surpassing the previous average price target of $19.81, the current average has increased by 21.91%.
<img src="https://www.benzinga.com/files/images/story/2024/1715274087_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Toast. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Jeff Cantwell</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Thomas Poutrieux</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Outperform</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Sheriq Sumar</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jeff Cantwell</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Toast. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Toast compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Toast's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Toast's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TOST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Toast analyst ratings.</a>
<h2>Get to Know Toast Better</h2>
Toast is a U.S.-based restaurant technology company that provides point-of-sale, payment processing, and various software services to 106,000 restaurant locations across the United States at the end of December 2023. The firm generates sales from software subscription fees, as a percentage take rate from each financial transaction it processes, from loan origination and servicing fees from its Toast Capital arm, and from hardware installation and professional services. Unlike competitors, Toast intermediates every payment transaction on its platform, processing some $126 billion in gross platform volume in 2023. The firm's product offerings span point-of-sale systems, inventory and payroll management, delivery integration, e-commerce ordering, reservation management, and loyalty programs.
<h3>Financial Insights: Toast</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Toast's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 3.76%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -7.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Toast's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.93%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Toast's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.14%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TOST

A Closer Look at 20 Analyst Recommendations For Toast

Across the recent three months, 4 analysts have shared their insights on Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.25, along with a high estimate of $24.00 and a low estimate of $20.00. Surpassing the previous average price target of $16.00, the current average has increased by 32.81%.
<img src="https://www.benzinga.com/files/images/story/2024/1715274078_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Oscar Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oscar Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Oscar Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Oscar Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Oscar Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OSCR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oscar Health analyst ratings.</a>
<h2>Delving into Oscar Health's Background</h2>
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
<h3>Understanding the Numbers: Oscar Health's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Oscar Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.8% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Oscar Health's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Oscar Health's ROE stands out, surpassing industry averages. With an impressive ROE of 19.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.42%, the company showcases effective utilization of assets.
Debt Management: Oscar Health's debt-to-equity ratio is below the industry average. With a ratio of 0.29, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OSCR

Decoding 4 Analyst Evaluations For Oscar Health

In the preceding three months, 4 analysts have released ratings for RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.75, a high estimate of $13.00, and a low estimate of $7.00. This current average represents a 7.89% decrease from the previous average price target of $9.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715274056_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of RumbleON by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Eric Wold</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$7.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to RumbleON. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RumbleON compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of RumbleON's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into RumbleON's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RMBL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RumbleON analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About RumbleON</h2>
RumbleON Inc is a USA-based online retailer that allows both consumers and dealers to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience. Its segments include power sports, automotive, and vehicle logistics. Powersports and automotive segments consist of the distribution of pre-owned vehicles. The Powersports segment that derives the majority of revenue consists of the distribution principally of motorcycles and other powersports vehicles, while the automotive segment distributes cars and trucks. The vehicle Logistics and transportation service segment offers nationwide automotive transportation services between dealerships and auctions.
<h3>Key Indicators: RumbleON's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: RumbleON's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -6.15%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: RumbleON's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -54.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RumbleON's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -120.06%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): RumbleON's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.98%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 7.31.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RMBL

Key Takeaways From RumbleON Analyst Ratings

PowerShares S&P 500 Low Volatility Portfolio

SPLV

CNBC Halftime Report Final Trades: Live Nation Entertainment, Delta Air Lines, Invesco S&P 500 Low Volatility ETF

Across the recent three months, 8 analysts have shared their insights on Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Choice Hotels Intl, revealing an average target of $130.75, a high estimate of $156.00, and a low estimate of $112.00. This upward trend is evident, with the current average reflecting a 4.7% increase from the previous average price target of $124.88.
<img src="https://www.benzinga.com/files/images/story/2024/1715274031_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Choice Hotels Intl by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlo Santarelli</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$112.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Michael Bellisario</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$146.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Bellisario</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$122.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$156.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Choice Hotels Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Choice Hotels Intl compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Choice Hotels Intl's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Choice Hotels Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Choice Hotels Intl analyst ratings.</a>
<h2>About Choice Hotels Intl</h2>
As of Dec. 31, 2023, Choice Hotels operated 633,000 rooms across 15 brands addressing the economy and midscale segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total domestic rooms), while Ascend and Cambria (7% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added around 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 79% of total rooms in 2023.
<h3>Choice Hotels Intl: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Choice Hotels Intl's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -0.99% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Choice Hotels Intl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Choice Hotels Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 53.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.25%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 47.24, Choice Hotels Intl faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Choice Hotels Intl Stands With Analysts

In the last three months, 4 analysts have published ratings on Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $2.69, a high estimate of $3.00, and a low estimate of $1.75. This upward trend is evident, with the current average reflecting a 8.47% increase from the previous average price target of $2.48.
<img src="https://www.benzinga.com/files/images/story/2024/1715274023_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lulus Fashion Lounge. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Randal Konik</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$1.75</td>
<td>$1.95</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$3.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$3.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lulus Fashion Lounge. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lulus Fashion Lounge compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Lulus Fashion Lounge's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lulus Fashion Lounge's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LVLU/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lulus Fashion Lounge analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Lulus Fashion Lounge</h2>
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
<h3>Breaking Down Lulus Fashion Lounge's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Lulus Fashion Lounge's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -17.59%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Lulus Fashion Lounge's net margin is impressive, surpassing industry averages. With a net margin of -9.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Lulus Fashion Lounge's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.5%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Lulus Fashion Lounge's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.56%, the company showcases efficient use of assets and strong financial health.
Debt Management: Lulus Fashion Lounge's debt-to-equity ratio is below the industry average. With a ratio of 0.64, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LVLU

The Latest Analyst Ratings For Lulus Fashion Lounge

In the latest quarter, 6 analysts provided ratings for Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Hain Celestial Group and provided 12-month price targets. The average target is $9.83, accompanied by a high estimate of $15.00 and a low estimate of $8.00. This current average has decreased by 19.43% from the previous average price target of $12.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1715274014_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Hain Celestial Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Vendetti</td>
<td>Maxim Group</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Baumgartner</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$10.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hain Celestial Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hain Celestial Group compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Hain Celestial Group's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hain Celestial Group's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HAIN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hain Celestial Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Hain Celestial Group's Background</h2>
The Hain Celestial Group Inc makes better-for-you natural and organic food and personal-care products. Some of the company's majority-recognized U.S. brands (55% of fiscal 2022 sales) are Celestial Seasonings, Terra, Garden of Eatin', Sensible Portions, Greek Gods yogurt, and Earth's baby food. Hain also maintains several brands in the U.K. (26% of sales), such as Ella's Kitchen baby food, New Covent Garden soup, Linda McCartney's plant-based meats, Sun-Pat nut butter, and Hartley's jams and gelatins. Its products can be found in traditional grocery stores, natural foods supermarkets, specialty health stores, mass-market retailers, club warehouses, drugstores, convenience stores, restaurants, and e-commerce sites.
<h3>Breaking Down Hain Celestial Group's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Hain Celestial Group's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -0.02%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Hain Celestial Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.98%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.37%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.61%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Hain Celestial Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HAIN

Navigating 6 Analyst Ratings For Hain Celestial Group

Kim Kardashian's eventful personal life has dominated every media corner for the last 17 years. She cleverly used the attention to become the queen of influencers with a Midas touch. A single story on her Instagram profile about a brand can take it from irrelevant to mainstream overnight.&nbsp;
Still, her business acumen little attention. Kardashian is a businesswoman who has built a multibillion-dollar company and invested in many startups. She now aims to do more of that through her venture capital firm. With as little as $1,000, <a href="https://www.benzinga.com/alternative-investments/startups">you can also get on the ground floor of various promising startups</a>.&nbsp;
Don't Miss:
<ul>
<li>Startup behind ‘the #1 free contractor app' grows 162% YoY,<a href="https://www.benzinga.com/go/contractor-offering"> opens its doors for investors at a $100 minimum</a>.</li>
<li>Invest in time-tested solution that aims to solve this $600 billion women&#8217;s health problem<a href="https://www.benzinga.com/money/rootless"> at 80 cents per share</a>.</li>
</ul>
<h2 class="wp-block-heading">Much More Than A Reality TV Star </h2>
The reality TV star founded a beauty company called KKW Beauty in 2017. It was later rebranded and evolved into SKKN by Kim. When she sold it in 2021, she bagged $200 million — chump change compared to SKIMS' latest evaluation. SKIMS is a shapewear and apparel brand Kardashian founded in 2019. It is currently worth $4 billion. 
Last year, Kardashian partnered with Jay Sammons, a 16-year veteran of private equity firm Carlyle, and started SKKY Partners. The venture capital firm aims to raise $1 billion to invest mainly in up-and-coming fashion, beauty, media, food and beverage companies. Kardashian could have used her influence to build a venture capital firm long ago, but it's no coincidence that she has chosen to do it now.&nbsp;
Trending: Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"> now harbor a huge investment opportunity</a>.
<h2 class="wp-block-heading">Seizing The Moment&nbsp;</h2>
Humanity is currently going through a period of unprecedented innovation. With modern technology, it often takes only a week to accomplish something that required months 10 years ago. This is a colossal driver of economic activity, and investing in startups is one of the best ways to take advantage of that.&nbsp;
Regular stocks are volatile and can rise and fall by 20% in a single day. Startups are a long option. If you anticipate a company's success early on, putting a few hundred bucks into it could prove to be the best financial decision of your life.&nbsp;
<h2 class="wp-block-heading">Like Kickstarter But With Ownership&nbsp;</h2>
<a href="https://www.benzinga.com/alternative-investments/startups">Equity crowdfunding options</a> are a relatively new way of investing in startups. It's similar to donating to Kickstarter and Indiegogo campaigns, but instead of getting a small token of gratitude, you get partial ownership of a company.&nbsp;
With entry points often as low as $100, investing is accessible to most people. With $1,000, you can create an entire portfolio and spread out the risk.&nbsp;
Keep Reading:
<ul>
<li>Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a></li>
<li>This Uber-for-moving startup is quietly taking the world by storm,<a href="https://www.benzinga.com/money/muvr"> here&#8217;s how anyone can invest for a limited time</a>.</li>
</ul>

Startups

Kim Kardashian Becomes An Angel Investor — What Kind Of Startups Are On Her Radar?

Former president Donald Trump's engagement with the cryptocurrency community has significantly fueled gains across his <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412858/trumps-crypto-portfolio-rebounds-with-1m-weekly-profit-which-crazy-new-currencies-does-he-">digital asset portfolio</a>, which soared by $1.3 million within a single day, reaching an impressive total of $6.581 million.
What Happened: This surge coincides with a notable rise in election-related meme coins following a pro-crypto speech by the former president.
The detailed breakdown of Trump's crypto assets includes 579,290 MAGA (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) tokens valued at $3.67 million, signifying his largest holding, according to <a href="https://platform.arkhamintelligence.com/explorer/entity/donald-trump">data </a>from Arkham Intelligence.
Additionally, Trump owns 418.655 units of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), worth about $1.27 million, and 374.5 Wrapped Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WETH</a>) tokens, valued at $1.11 million. 
His portfolio also includes 950,000 BABYTRUMP (CRYPTO: BABYTRUMP) tokens, worth approximately $49.9K, and a smaller stake of 5.250 Polygon (CRYPTO: MATIC) tokens, totaling about $3.56K.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38728621/spot-bitcoin-etfs-clock-11m-net-inflows-on-wednesday-as-grayscale-shifts-focus-to-spot-eth">Spot Bitcoin ETFs Clock $11M Net Inflows On Wednesday As Grayscale Shifts Focus To Spot Ether ETF</a>
Why It Matters: Trump&#8217;s recent speech, in which he declared his campaign's readiness to accept crypto donations and encouraged pro-crypto voters to support him, significantly influenced the rally.
He emphasized the importance of cryptocurrency to his supporters, stating, "If you can't, I'll make sure you can. Can we donate to the Trump campaign using crypto? I believe the answer is yes." 
His direct appeal and the subsequent media coverage acted as catalysts, driving substantial increases in meme coins like Doland Tremp (TREMP), which surged over 124% in response.
This surge and Trump's direct involvement in crypto advocacy highlight the growing intersection between politics and cryptocurrency markets. 
What&#8217;s Next: These developments are expected to be a focal point at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where the impact of political figures and policies on the dynamic landscape of digital assets will be explored in depth.
Read Next:<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38728088/jpmorgan-analysts-optimistic-about-future-approval-of-spot-ether-etfs-despite-regulatory-h"> JPMorgan Analysts Optimistic About Future Approval Of Spot Ether ETFs Despite Regulatory Hurdles</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$TRUMP

$WETH

How Much Did Donald Trump's Crypto Portfolio Pump After He Said He's 'Fine With It'?

Raymond James analyst Brian Vaccaro upgrades Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) from Market Perform to Outperform and announces $42 price target.

Upgrades

Price Target

CAKE

Raymond James Upgrades Cheesecake Factory to Outperform, Announces $42 Price Target

Oppenheimer analyst Ian Zaffino maintains Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) with a Outperform and lowers the price target from $29 to $20.

CCSI

Oppenheimer Maintains Outperform on Consensus Cloud Solns, Lowers Price Target to $20

Oppenheimer analyst Martin Yang maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $85 to $97.

Oppenheimer Maintains Outperform on AppLovin, Raises Price Target to $97

Hilton Grand Vacations Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) first-quarter FY24&nbsp;sales rose to $1.16 billion from $934 million a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38727504/hilton-grand-vacations-reports-first-quarter-2024-results" rel="noreferrer noopener">the consensus of $1.12 billion</a>.
Revenues were affected by a net recognition of $2 million in the current period compared to a net recognition of $4 million in the same period in 2023.
Real estate sales and financing segment revenues totaled $687 million, an increase of $137 million from last year.&nbsp;
Total contract sales increased by $108 million Y/Y to $631 million, including $136 million contributed by Bluegreen Vacations.
Consolidated Net Owner Growth (NOG)&nbsp;for the legacy HGV-DRI business for the 12 months ended March 31, 2024, was 2%.&nbsp;Member&nbsp;count stood at 718,000.
Adjusted EBITDA rose to $273 million from $218 million a year ago. Adjusted EPS of $0.95&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the consensus of $0.72.</a>
The company held $355 million in cash and equivalents plus a total restricted cash of $323 million as of&nbsp;March-end.
In the first quarter,&nbsp;the company repurchased 2.3 million shares for $99 million.&nbsp;
Through April 30, 2024, Hilton Grand bought back around 1.1 million shares for $47 million and currently has shares worth $213 million remaining available under the 2023 repurchase Plan.
Mark Wang, president&nbsp;and&nbsp;CEO, said, &#8220;As we look out to the rest of the year, we&#8217;re focused on integrating Bluegreen Vacations and advancing our rebranding&nbsp;plans,&nbsp;while engaging with our new partners to explore new avenues for growth.&nbsp;In addition, our recently announced partnership with Great Wolf Lodge supports our commitment to expanding our lead channels and tour&nbsp;flow,&nbsp;while also providing our members with new compelling vacation options.&#8221;
Outlook: Hilton Grand Vacations reiterated FY24 guidance&nbsp;for Adjusted EBITDA, excluding deferrals and recognitions, of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1.2 billion&nbsp;to&nbsp;$1.26 billion.</a>
In January 2024, HGV completed the acquisition of Bluegreen Vacations Holding.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37943510/hilton-grand-vacations-to-benefit-from-selling-owned-inventory-analyst-says" rel="noreferrer noopener">Hilton Grand Vacations To Benefit From Selling Owned Inventory, Analyst Says</a>
Price Action: HGV shares are up 0.90% at $43.79 at the last check Thursday.
Photo via Wikimedia Commons

Earnings

Equities

Large Cap

Guidance

Checking In: Hilton Grand Vacations' Q1 Performance Exceeds Estimates, Backs Outlook

Oppenheimer analyst Jason Helfstein maintains IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) with a Outperform and raises the price target from $65 to $75.

Oppenheimer Maintains Outperform on IAC, Raises Price Target to $75

Oppenheimer analyst Steven Lichtman maintains BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Outperform and raises the price target from $10 to $11.

BWAY

Oppenheimer Maintains Outperform on BrainsWay, Raises Price Target to $11

RBC Capital analyst Daniel Perlin maintains Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) with a Sector Perform and raises the price target from $302 to $310.

CPAY

RBC Capital Maintains Sector Perform on Corpay, Raises Price Target to $310

China's stock market has been a hot topic in 2024, and for good reason. After a rough start, marked by a sharp decline in January due to derivative-related issues, Chinese stocks have staged <a href="https://www.benzinga.com/topic/china">an impressive comeback</a>.
<h1 class="wp-block-heading">China ETFs Outperform U.S.</h1>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="629" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09110943/Screenshot-2024-05-09-at-8.39.25-PM.png" alt="" class="wp-image-330885" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09110943/Screenshot-2024-05-09-at-8.39.25-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09110943/Screenshot-2024-05-09-at-8.39.25-PM-300x216.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart: Benzinga Pro</a>
Key ETFs such as KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>), KraneShares Bosera MSCI China A 50 Connect Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBA#NYSE">KBA</a>), iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>), and iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) have outperformed major U.S.-equity ETFs, such as the S&amp;P 500 index-tracking SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), since February, signaling a potential shift in the market landscape.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="629" height="452" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09111254/Screenshot-2024-05-09-at-8.42.37-PM.png" alt="" class="wp-image-330893" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09111254/Screenshot-2024-05-09-at-8.42.37-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09111254/Screenshot-2024-05-09-at-8.42.37-PM-300x216.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart: Benzinga Pro</a>
Also Read: <a href="https://www.benzinga.com/markets/asia/23/04/31846112/chinas-strong-q1-economic-rebound-sparks-optimism-for-apple-tesla-and-these-companies">China&#8217;s Strong Q1 Economic Rebound Sparks Optimism for Apple, Tesla And These Companies</a>
<h1 class="wp-block-heading">KraneShares&#8217; CIO Gives 5 Reasons To Invest</h1>
In a recent post, Brendan Ahern, chief investment officer at KraneShares, <a href="https://kraneshares.com/5-reasons-chinas-recent-stock-market-rally-is-fundamentally-different/#">highlighted</a> five key catalysts driving the current China market rebound.
<ol>
<li>Government Support as a Catalyst: One of the fundamental differences in this rally is the proactive stance of the Chinese government in stabilizing the market. State-linked entities like Central Huijin Investments have openly announced purchases of mainland-listed ETFs and increased holdings in mainland bank stocks. This level of transparency and support can instill confidence in investors and provide a strong foundation for the market to grow. </li>
<li>Global Investors' Changing Sentiments: Global investors are starting to reallocate their investments back into Chinese equities. Earlier in the year, many investors were cautious due to trade tensions and regulatory uncertainties. However, with signs of easing tensions and supportive policies, there is a growing interest in Chinese stocks. This shift in sentiment could lead to increased capital inflows into Chinese markets, driving up stock prices. </li>
<li>Policy Reforms and Market Improvements: The Chinese government has issued &#8220;<a href="https://kraneshares.com/5-reasons-chinas-recent-stock-market-rally-is-fundamentally-different/#">9 Key Points</a>&#8221; to improve the country&#8217;s capital markets, focusing on controlling IPO supply, encouraging dividends, and enhancing corporate governance. These reforms are aimed at creating a more transparent and investor-friendly market environment, which could attract more investors, both domestic and international. </li>
<li>Economic Recovery and Consumer Confidence: China&#8217;s economy is showing signs of recovery, with <a href="http://China's Strong Q1 Economic Rebound Sparks Optimism for Apple, Tesla And These Companies">GDP exceeding expectations</a> in the first quarter of 2024. Consumer confidence is also on the rise, with increased spending on services like dining and travel. This uptick in economic activity could translate into higher corporate earnings and stock prices, making it an opportune time for investors to enter the market. </li>
<li>Attractive Valuations and Buyback Opportunities: Despite the recent rally, valuations in certain sectors of the Chinese market remain attractive. Many companies are taking advantage of this by <a href="https://www.benzinga.com/news/24/04/38065328/alibabas-bold-actions-4-8b-stock-repurchase-and-revolutionary-one-hour-global-delivery-plan">buying back their stock</a>, particularly in the internet sector. This not only demonstrates confidence in their own businesses but also reduces the supply of shares in the market, potentially driving up prices.</li>
</ol>
These, according to Ahern, are compelling reasons why this resurgence in Chinese equities could offer lucrative opportunities for investors.
The recent resurgence in China's stock market presents an exciting opportunity for investors. With government support, changing investor sentiments, policy reforms, economic recovery and attractive valuations, Chinese equities could be poised for further growth.
Investors looking to capitalize on this trend should consider adding exposure to Chinese stocks in their portfolios, particularly through ETFs KWEB, FXI, MCHI and KBA, which offer diversified exposure to the Chinese market.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37028937/is-chinas-stock-market-poised-for-a-turnaround-analyst-points-to-3-promising-signs-">Is China&#8217;s Stock Market Poised For A Turnaround? Analyst Points To 3 Promising Signs Amid Policy Shifts</a>
Photo: Chonrawit Boonprakob via Shutterstock

Analyst Color

Asia

Broad U.S. Equity ETFs

Emerging Markets

Emerging Market ETFs

Global

Opinion

ETFs

KWEB

MCHI

The Dragon Awakens: KraneShares CIO Names 5 Reasons To Invest In China's Stock Market Rebound

Oppenheimer analyst Jeff Jones maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Outperform and lowers the price target from $5 to $4.

MCRB

Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $4

Craig-Hallum analyst Connor Chamberlain reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and maintains $15 price target.

Reiteration

CDNA

Craig-Hallum Reiterates Buy on CareDx, Maintains $15 Price Target

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Outperform and lowers the price target from $36 to $31.

VRDN

Oppenheimer Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $31

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a price target of...

Biomea Fusion (BMEA) Receives a Buy from Scotiabank

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biomea Fusion (BMEA – Research Report) and GoodRx Holdings (GDRX ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)

Biomea Fusion drops as JPMorgan downgrades on data for lead asset

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts

DJT, BGFV and REAL are among after hour movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biomea Fusion (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmea-stock-quote/">BMEA</a>) just reported results for the first quarter of 2024.<ul><li>Biomea Fusion reported earnings per share of -$1.09. This was below the analyst estimate for EPS of -99 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bmea-stock-earnings-biomea-fusion-for-q1-of-2024/">BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024

Biomea Fusion GAAP EPS of -$1.09 misses by $0.02

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a price target of $3...

Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biomea Fusion (BMEA – Research Report), Repligen (RGEN – Research...

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

Scotiabank analyst George Farmer maintained a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $41.00. The comp...

Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)

AGEN

AXTI

BGFV

FOUR

GDRX

MCBC

PSTX

REAL

RGEN

RNAC

ROAD

TERN

TPIC

Press Releases

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Health Care

General

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Biomea Fusion Stock (NASDAQ:BMEA), Short Interest Report

People Also Watch